[go: up one dir, main page]

CO5640102A2 - Composiciones farmaceuticas de agonista parcial de 5ht4 - Google Patents

Composiciones farmaceuticas de agonista parcial de 5ht4

Info

Publication number
CO5640102A2
CO5640102A2 CO04067463A CO04067463A CO5640102A2 CO 5640102 A2 CO5640102 A2 CO 5640102A2 CO 04067463 A CO04067463 A CO 04067463A CO 04067463 A CO04067463 A CO 04067463A CO 5640102 A2 CO5640102 A2 CO 5640102A2
Authority
CO
Colombia
Prior art keywords
composition according
partial agonist
weight
pharmaceutical compositions
percent
Prior art date
Application number
CO04067463A
Other languages
English (en)
Inventor
Jerome Aubert
Christian Vitzling
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CO5640102A2 publication Critical patent/CO5640102A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

1.- Una composición farmacéutica sólida para administración oral, la cual comprende:un agonista parcial de 5-HT4 en forma de base o de sal, en una cantidad de hasta el 10 por ciento en peso,un diluyente en una cantidad del 70 al 90 por ciento en peso, un desintegrante en una cantidad menor al 15 por ciento en peso, y en donde las cantidades en peso se basan en el peso total de la composición.2.- Una composición de acuerdo con la reivindicación 1, en donde el agonista parcial de 5-HT4 es tegaserod.3.- Una composición de acuerdo con la reivindicación 1 ó 2, la cual además comprende un abrillantador.4.- Una composición de acuerdo con cualquiera de las reivindicaciones precedentes, la cual además comprende un lubricante.5.- Una composición de acuerdo con cualquiera de las reivindicaciones precedentes, la cual además comprende un aglutinante.6.- Una composición de acuerdo con cualquiera de las reivindicaciones 2-5, en donde el tegaserod está en la forma de la sal de maleato.
CO04067463A 2001-12-21 2004-07-15 Composiciones farmaceuticas de agonista parcial de 5ht4 CO5640102A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01403339A EP1321142A1 (en) 2001-12-21 2001-12-21 Solid pharmaceutical composition for oral administration of Tegaserod

Publications (1)

Publication Number Publication Date
CO5640102A2 true CO5640102A2 (es) 2006-05-31

Family

ID=8183045

Family Applications (1)

Application Number Title Priority Date Filing Date
CO04067463A CO5640102A2 (es) 2001-12-21 2004-07-15 Composiciones farmaceuticas de agonista parcial de 5ht4

Country Status (31)

Country Link
US (2) US20050106236A1 (es)
EP (2) EP1321142A1 (es)
JP (1) JP4718776B2 (es)
KR (1) KR100980144B1 (es)
CN (1) CN100464749C (es)
AR (1) AR037937A1 (es)
AT (1) ATE320807T1 (es)
AU (1) AU2002361198B2 (es)
BR (1) BR0215148A (es)
CA (1) CA2470668C (es)
CO (1) CO5640102A2 (es)
CY (1) CY1105559T1 (es)
DE (1) DE60210139T2 (es)
DK (1) DK1458377T3 (es)
EC (1) ECSP105163A (es)
EG (1) EG24194A (es)
ES (1) ES2258171T3 (es)
HU (1) HU226589B1 (es)
IL (2) IL162451A0 (es)
MX (1) MXPA04006157A (es)
MY (1) MY139546A (es)
NO (1) NO20042779L (es)
NZ (1) NZ533585A (es)
PE (1) PE20030872A1 (es)
PL (1) PL369509A1 (es)
PT (1) PT1458377E (es)
RU (1) RU2322978C2 (es)
SI (1) SI1458377T1 (es)
TW (1) TWI260221B (es)
WO (1) WO2003053432A1 (es)
ZA (1) ZA200404467B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1165293C (zh) * 1998-08-21 2004-09-08 诺瓦提斯公司 5ht4激动剂或拮抗剂的新型口服制剂
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
ATE365174T1 (de) 2003-01-28 2007-07-15 Microbia Inc Zusammensetzungen zur behandlung von gastrointestinalen störungen
AU2003222439A1 (en) * 2003-03-25 2004-10-18 Hetero Drugs Limited Novel crystalline forms of tegaserod maleate
EP1629280A2 (en) * 2003-05-21 2006-03-01 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine (serotonin) receptor 4 (5-ht4)
AR045081A1 (es) * 2003-07-24 2005-10-12 Novartis Ag Modificaciones estables de maleato de hidrogeno de tegaserod
TWI344363B (en) 2003-09-12 2011-07-01 Amgen Inc Rapid dissolution formulation of a calcium receptor-active compound
WO2005058819A2 (en) * 2003-12-16 2005-06-30 Teva Pharmaceutical Industries Ltd. Polymorphic forms of tegaserod base and salts thereof
CZ298399B6 (cs) * 2005-05-02 2007-09-19 Zentiva, A. S. Zpusob prípravy 2-[(5-methoxy-1 H-indol-3-yl) methylen]-N-pentylkarbazimidamidu (tegaserodu)
US20070259052A1 (en) 2006-05-05 2007-11-08 Shire International Licensing B.V. Assay for lanthanum hydroxycarbonate
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CA2688161C (en) 2007-06-04 2020-10-20 Kunwar Shailubhai Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
KR101683318B1 (ko) 2008-12-31 2016-12-07 알데릭스, 인코포레이티드 체액 저류 또는 염 과부하와 연관된 장애 및 위장관 장애의 치료 시에 ｎｈｅ-매개된 역수송을 억제하는 화합물 및 방법
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2014029983A1 (en) 2012-08-21 2014-02-27 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
EP2968439A2 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
RU2675364C2 (ru) 2013-04-12 2018-12-19 Арделикс, Инк Nhe3-связывающие соединения и способы ингибирования транспорта фосфатов
CN104922083B (zh) * 2015-04-15 2017-12-22 湖南尔康湘药制药有限公司 磺胺嘧啶片及其制备方法
WO2017064538A1 (en) * 2015-10-16 2017-04-20 Nobel Ilac Sanayii Ve Ticaret A.S. Pharmaceutical compositions of nilotinib hydrochloride
CN118221656A (zh) 2017-01-09 2024-06-21 阿德利克斯股份有限公司 可用于治疗胃肠道病症的化合物
US11147884B2 (en) 2017-01-09 2021-10-19 Ardelyx, Inc. Inhibitors of NHE-mediated antiport

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0820586A (ja) * 1994-07-05 1996-01-23 Sanwa Kagaku Kenkyusho Co Ltd １−アザビシクロ［３．３．０］オクタン誘導体、その塩及び製法並びに用途
IL117438A (en) * 1995-03-16 2001-12-23 Lilly Co Eli Indazolecarboxamides, their preparation and pharmaceutical compositions containing them
JPH09194374A (ja) * 1995-11-14 1997-07-29 Taisho Pharmaceut Co Ltd 消化器疾患治療剤
DE69713948D1 (de) * 1996-04-23 2002-08-22 Janssen Pharmaceutica Nv Rasch-freisetzende pH-unabhängige feste Dosisformen enthaltend Cisaprid
US5739151A (en) * 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
CN1165293C (zh) * 1998-08-21 2004-09-08 诺瓦提斯公司 5ht4激动剂或拮抗剂的新型口服制剂
US6465502B1 (en) * 1998-12-23 2002-10-15 Novartis Ag Additional therapeutic use
WO2000057857A1 (en) * 1999-03-25 2000-10-05 Yuhan Corporation Rapidly disintegrable tablet for oral administration
EP1200091B1 (en) * 1999-08-03 2008-07-02 Lilly Icos LLC Pharmaceutical composition comprising tadalafil

Also Published As

Publication number Publication date
CN1606438A (zh) 2005-04-13
AU2002361198A1 (en) 2003-07-09
EP1458377B1 (en) 2006-03-22
ES2258171T3 (es) 2006-08-16
EP1321142A1 (en) 2003-06-25
NO20042779L (no) 2004-09-17
DE60210139T2 (de) 2006-08-17
HUP0402492A2 (hu) 2005-07-28
PL369509A1 (en) 2005-04-18
US20090104263A1 (en) 2009-04-23
IL162451A0 (en) 2005-11-20
ZA200404467B (en) 2006-05-31
NZ533585A (en) 2006-04-28
HUP0402492A3 (en) 2008-04-28
KR20040066922A (ko) 2004-07-27
SI1458377T1 (sl) 2006-08-31
PE20030872A1 (es) 2003-11-24
US20050106236A1 (en) 2005-05-19
ECSP105163A (es) 2010-07-30
CA2470668C (en) 2011-07-05
AU2002361198B2 (en) 2006-06-08
MY139546A (en) 2009-10-30
DE60210139D1 (de) 2006-05-11
ATE320807T1 (de) 2006-04-15
EP1458377A1 (en) 2004-09-22
CN100464749C (zh) 2009-03-04
CA2470668A1 (en) 2003-07-03
PT1458377E (pt) 2006-07-31
EG24194A (en) 2008-10-14
JP4718776B2 (ja) 2011-07-06
AR037937A1 (es) 2004-12-22
RU2322978C2 (ru) 2008-04-27
DK1458377T3 (da) 2006-06-12
IL162451A (en) 2009-02-11
BR0215148A (pt) 2004-10-19
TW200410684A (en) 2004-07-01
WO2003053432A1 (en) 2003-07-03
RU2004122631A (ru) 2005-08-10
JP2005516946A (ja) 2005-06-09
MXPA04006157A (es) 2004-10-27
KR100980144B1 (ko) 2010-09-03
TWI260221B (en) 2006-08-21
CY1105559T1 (el) 2010-07-28
HU226589B1 (en) 2009-04-28

Similar Documents

Publication Publication Date Title
CO5640102A2 (es) Composiciones farmaceuticas de agonista parcial de 5ht4
BR0316532A (pt) Composições farmacêuticas compreendendo, um composto de droga básico, respectivamente um ácido, um tensoativo e um ácido solúvel em água fisiologicamente tolerável, respectivamente, uma base
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
MX2008001606A (es) Piperazinas substituidas como antagonistas de receptor de glutamato metabotropico.
EA200700566A1 (ru) Фармацевтические композиции, включающие леветирацетам, и способы их получения
PA8586401A1 (es) 4-piperazinilbencenosulfonilindoles y uso de los mismos
MY151003A (en) Stable pharmaceutical composition comprising a pyrimidine-sulfamide
DK1856090T3 (da) Substituerede thiophen-derivater som glucagon-receptorantagonister, fremstilling og terapeutiske anvendelser
DK1723144T3 (da) Yderligere heteropolycykliske forbindelser og anvendelse deraf som metabotropiske glutamareceptor-antagonister
EA200701357A1 (ru) Композиции и способы применения модулятора рецептора 5ht
HK1076605A1 (en) Formulations
CO5390076A1 (es) Composiciones farmaceuticas
IL180144A0 (en) Compositions comprising strontium and vitamin d and uses thereof
EA200400357A1 (ru) Дезинтегрирующиеся в ротовой полости композиции валдекоксиба
UA84896C2 (ru) Производные гидронопола как агонисты человеческих рецепторов orl1
TNSN06012A1 (en) Emulsifying systems containing azetidine derivatives
GB2421241A (en) Disulfide, sulfide, sulfoxide, and sulfone derivatives of cyclic sugars and uses thereof
BRPI0413676A (pt) composto, e, composição farmacêutica
PA8605101A1 (es) 4-(aminometil)-piperidin benzamidas como antagonista de 5ht4
MX2008001608A (es) Piperazinas acetilenicas como antagonistas de receptor de glutamato metabotropico.
AU2003208395A8 (en) Pharmaceutical compositions comprising 17alpha-furanylesters of 17beta-carbothioate androstanes with a muscarinic receptor antagonist
MX2007001992A (es) Antagonistas del receptor 5-ht7.
IL162983A (en) Use of imatinib for the manufacture of pharmaceutical compositions for the treatment of rheumatoid arthritis
RS56104A (en) Imidazoquinoline derivatives
BRPI0408446A (pt) tablete de limpeza

Legal Events

Date Code Title Description
FC Application refused